Menu
Back to User profile » Dr Paul Karpecki
Papers published by Dr Paul Karpecki:
Considerations for the Identification and Management of Geographic Atrophy: Recommendations from an Expert Panel
Regillo CD, Nijm LM, Shechtman DL, Kaiser PK, Karpecki PM, Ryan EH, Ip MS, Yeu E, Kim T, Rafieetary MR, Donnenfeld ED
Clinical Ophthalmology 2024, 18:325-335
Published Date: 2 February 2024
Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis
Farid M, Ayres BD, Donnenfeld E, Gaddie IB, Gupta PK, Holland E, Lindstrom R, Pflugfelder SC, Karpecki PM, Nichols KK, Starr CE, Yeu E
Clinical Ophthalmology 2023, 17:667-679
Published Date: 27 February 2023
The Prevalence of Demodex Blepharitis in US Eye Care Clinic Patients as Determined by Collarettes: A Pathognomonic Sign
Trattler W, Karpecki P, Rapoport Y, Sadri E, Schachter S, Whitley WO, Yeu E
Clinical Ophthalmology 2022, 16:1153-1164
Published Date: 15 April 2022
Interpersonal Communication in Eye Care: An Analysis of Potential Impacts on Cataract Surgery Candidates’ Expectations and Behaviors
Hellem A, LaBelle S, Matossian C, Karpecki P
Clinical Ophthalmology 2022, 16:1003-1008
Published Date: 5 April 2022
Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies
Nichols KK, Donnenfeld ED, Lau C, Syntosi A, Karpecki P, Hovanesian JA
Clinical Ophthalmology 2022, 16:909-916
Published Date: 25 March 2022
Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure
Clark D, Karpecki P, Salapatek AM, Sheppard JD, Brady TC
Clinical Ophthalmology 2022, 16:15-23
Published Date: 4 January 2022
A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
McMullin D, Clark D, Cavanagh B, Karpecki P, Brady TC
Clinical Ophthalmology 2021, 15:3889-3900
Published Date: 22 September 2021
Presbyopia – A Review of Current Treatment Options and Emerging Therapies
Katz JA, Karpecki PM, Dorca A, Chiva-Razavi S, Floyd H, Barnes E, Wuttke M, Donnenfeld E
Clinical Ophthalmology 2021, 15:2167-2178
Published Date: 24 May 2021
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
Sheppard J, Bergmann M, Schechter BA, Luchs J, Ogundele A, Karpecki P
Clinical Ophthalmology 2021, 15:129-140
Published Date: 12 January 2021
Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial
Pepose JS, Hartman PJ, DuBiner HB, Abrams MA, Smyth-Medina RJ, Moroi SE, Meyer AR, Sooch MP, Jaber RM, Charizanis K, Klapman SA, Amin AT, Yousif JE, Lazar ES, Karpecki PM, Slonim CB, McDonald MB
Clinical Ophthalmology 2021, 15:79-91
Published Date: 8 January 2021
A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare® System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease
Karpecki P, Wirta D, Osmanovic S, Dhamdhere K
Clinical Ophthalmology 2020, 14:4551-4559
Published Date: 30 December 2020
A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
Periman LM, Mah FS, Karpecki PM
Clinical Ophthalmology 2020, 14:4187-4200
Published Date: 2 December 2020
Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
Shen Lee B, Kabat AG, Bacharach J, Karpecki P, Luchs J
Clinical Ophthalmology 2020, 14:119-126
Published Date: 14 January 2020
Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
White DE, Zhao Y, Ogundele A, Fulcher N, Acs A, Moore-Schiltz L, Karpecki PM
Clinical Ophthalmology 2019, 13:2285-2292
Published Date: 22 November 2019
A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
Karpecki PM, Weiss SL, Kramer WG, O'Connor P, Evans D, Johnston J, Jasper AL, Justice A, Ogundele AB, Devries D
Clinical Ophthalmology 2019, 13:591-596
Published Date: 5 April 2019